Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs

•An inactivated whole-virion TBEV vaccine candidate for dogs was developed.•The vaccine candidate was tested in mice and in dogs.•The vaccine was well tolerated and elicited production of neutralizing anti-TBEV antibodies.•Vaccination of mice provided complete protection against lethal TBEV infectio...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2023-10, Vol.41 (42), p.6150-6155
Main Authors: Salat, Jiri, Hunady, Milan, Svoboda, Pavel, Strelcova, Lucie, Strakova, Petra, Fortova, Andrea, Palus, Martin, Ruzek, Daniel
Format: Article
Language:English
Subjects:
Animals
Antibodies
Antigens
Apathy
Arachnids
Bacterial infections
Dogs
Effectiveness
Encephalitis
Females
Immunization
Immunogenicity
Infections
Males
Tick-borne encephalitis
Vaccine
Vaccines
Viremia
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•An inactivated whole-virion TBEV vaccine candidate for dogs was developed.•The vaccine candidate was tested in mice and in dogs.•The vaccine was well tolerated and elicited production of neutralizing anti-TBEV antibodies.•Vaccination of mice provided complete protection against lethal TBEV infection.•Vaccination of dogs prevented the development of viremia after challenge infection. Tick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2023.09.019